Free Trial
NASDAQ:GRFS

Grifols (GRFS) Stock Price, News & Analysis

Grifols logo
$9.07 -0.07 (-0.71%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Grifols Stock (NASDAQ:GRFS)

Key Stats

Today's Range
$9.01
$9.19
50-Day Range
$6.95
$9.14
52-Week Range
$6.19
$9.96
Volume
191,164 shs
Average Volume
1.12 million shs
Market Capitalization
$6.24 billion
P/E Ratio
7.76
Dividend Yield
N/A
Price Target
$10.30
Consensus Rating
Buy

Company Overview

Grifols Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
87th Percentile Overall Score

GRFS MarketRank™: 

Grifols scored higher than 87% of companies evaluated by MarketBeat, and ranked 199th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Grifols has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Grifols has only been the subject of 1 research reports in the past 90 days.

  • Read more about Grifols' stock forecast and price target.
  • Earnings Growth

    Earnings for Grifols are expected to grow by 29.63% in the coming year, from $0.81 to $1.05 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Grifols is 7.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.66.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Grifols is 7.76, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.66.

  • Price to Earnings Growth Ratio

    Grifols has a PEG Ratio of 0.33. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Grifols has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Grifols' valuation and earnings.
  • Percentage of Shares Shorted

    1.07% of the float of Grifols has been sold short.
  • Short Interest Ratio / Days to Cover

    Grifols has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Grifols has recently decreased by 10.39%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Grifols does not currently pay a dividend.

  • Dividend Growth

    Grifols does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Grifols is 30.77%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Grifols will have a dividend payout ratio of 34.29% next year. This indicates that Grifols will be able to sustain or increase its dividend.

  • Read more about Grifols' dividend.
  • Percentage of Shares Shorted

    1.07% of the float of Grifols has been sold short.
  • Short Interest Ratio / Days to Cover

    Grifols has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Grifols has recently decreased by 10.39%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Grifols has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Grifols this week, compared to 4 articles on an average week.
  • Search Interest

    1 people have searched for GRFS on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Grifols insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.19% of the stock of Grifols is held by insiders.

  • Read more about Grifols' insider trading history.
Receive GRFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Grifols and its competitors with MarketBeat's FREE daily newsletter.

GRFS Stock News Headlines

Banks aren’t ready for this altcoin—are you?
Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly positioned to fill it…
Grifols: If This Works Out, It Has Massive Upside
See More Headlines

GRFS Stock Analysis - Frequently Asked Questions

Grifols' stock was trading at $7.44 at the beginning of 2025. Since then, GRFS stock has increased by 22.0% and is now trading at $9.0750.

Grifols, S.A. (NASDAQ:GRFS) released its earnings results on Tuesday, May, 4th. The biotechnology company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.22 by $0.01. The biotechnology company earned $1.43 billion during the quarter.

Shares of Grifols split before market open on Monday, January 4th 2016.The 2-1 split was announced on Thursday, December 3rd 2015. The newly minted shares were distributed to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Grifols subsidiaries include these companies: Biotest US Corporation, Haema AG, Goetech LLC (D/B/A Medkeeper), Kiro Robotics, Progenika Biopharma, Araclon Biotech, Talecris Biotherapeutics, and more.

Shares of GRFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Grifols investors own include Johnson & Johnson (JNJ), Alibaba Group (BABA), Taiwan Semiconductor Manufacturing (TSM), JPMorgan Chase & Co. (JPM), Deckers Outdoor (DECK), Vale (VALE) and Meta Platforms (META).

Company Calendar

Last Earnings
5/04/2021
Today
7/05/2025
Next Earnings (Estimated)
7/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GRFS
Employees
23,822
Year Founded
1909

Price Target and Rating

Average Stock Price Target
$10.30
High Stock Price Target
$10.30
Low Stock Price Target
$10.30
Potential Upside/Downside
+13.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
7.76
Forward P/E Ratio
11.20
P/E Growth
0.33
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.81 billion
Cash Flow
$0.94 per share
Price / Cash Flow
9.70
Book Value
$13.55 per share
Price / Book
0.67

Miscellaneous

Free Float
686,249,000
Market Cap
$6.24 billion
Optionable
Optionable
Beta
0.55

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:GRFS) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners